“The Global Pharmaceutical Wholesale & Distribution market is estimated to be worth $1.3bn in 2023” says new Visiongain report

03 October 2018
Pharma

Visiongain has launched a new pharma report: Top 20 Pharmaceutical Wholesale & Distribution Organizations 2018: Branded Drugs, Generic Drugs, Leading Companies

Growth in the global pharmaceutical wholesale and distribution market has remained steady in recent years. Growth is being held back by government price reductions and generic substitution of expensive branded drugs. However, the global demand for prescription medication is increasing. The ageing population in the developed markets is resulting in increasing prevalence of age-related diseases, which require medical treatment. In the emerging markets, the rapidly expanding middle class and increasing spending on healthcare is creating a high demand for medication. The pharmaceutical wholesale and distribution market is poised for strong growth.

The lead analyst of the report commented "Currently, most emerging pharmaceutical wholesale markets are much more fragmented than their developed counterparts. For example, in the US, the top 3 companies account for more than 95% of the country’s total market. China has seen rapid consolidation in recent years; there, the top 2 companies currently account for more than 45% of the market. The Chinese market will see further rapid consolidation during the forecast period.

During the forecast period there will be significant consolidation in the emerging markets. This will lead to a greater number of national wholesalers, able to serve all regions with greater efficiency and lower costs."

Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Anda Inc., Cardinal Health, CR Pharmaceutical, CuraScript Special, Fortissa Limited, H.D. Smith, Mawdsley-Brooks & Co. Ltd., McKesson, MEDIPAL HOLDINGS, Morris & Dickson Co. LLC, North Carolina Mutual Wholesale Drug, Prodigy Health, Shanghai Pharmaceutical Holdings., SINOPHARM, Smith Drug Company, SUZUKEN, The PHOENIX Group, Walgreens Boots Alliance

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focussing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1